伦敦和纽约 - Compass Pathways plc (NASDAQ:CMPS) 通过行权2025年1月13日发行的35,059,448份权证筹集了约2亿美元资金,该公司在新闻稿中表示。 这家生物技术公司正在向特定机构投资者发行15,160,619份美国存托股份,以及可购买至多19,898,829份美国存托股份的预付费权证以代替美国存托股份。 Compass ...

伦敦 - 生物技术公司 Compass Pathways plc (NASDAQ:CMPS) 周三宣布,已完成1,750万股美国存托股份的公开发行定价,每股ADS定价为$8.00。该发行还包括向特定机构投资者发行预付款权证,可购买最多125万股ADS,每份权证价格为$7.9999。根据 InvestingPro ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were ...

Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis. Read more on CMPS stock here.

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

Today, Compass updated investors on its drug trial progress, and the stock shot higher. Compass announced two Phase 3 trials ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...

The company's fresh look at psychedelic drugs is attracting lots of attention. Can the highly refined version of magic mushrooms that Compass Pathways is developing for depression give your portfolio ...